Denali Therapeutics Inc. (DNLI) EPS Estimated At $-0.21

October 14, 2018 - By Lawrence Diaz

Analysts expect Denali Therapeutics Inc. (NASDAQ:DNLI) to report $-0.21 EPS on November, 8.After having $-0.59 EPS previously, Denali Therapeutics Inc.’s analysts see -64.41 % EPS growth. The stock increased 2.48% or $0.41 during the last trading session, reaching $16.94. About 307,444 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company has market cap of $1.61 billion. The firm offers leucine-rich repeat kinase 2 inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Another recent and important Denali Therapeutics Inc. (NASDAQ:DNLI) news was published by Businesswire.com which published an article titled: “CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials” on October 03, 2018.

Denali Therapeutics Inc. (NASDAQ:DNLI) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>